Sangamo Therapeutics, Inc. reported impairment results for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment of long-lived assets of $0.3 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3986 USD | -5.86% |
|
-11.52% | -26.63% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.63% | 82.71M | |
+16.13% | 122B | |
+19.65% | 113B | |
+19.30% | 26.49B | |
-23.84% | 19.4B | |
-17.98% | 16.24B | |
-45.95% | 15.15B | |
-19.28% | 15.4B | |
+63.81% | 14.93B | |
+1.94% | 13.52B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023